The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPAR?2 to induce the formation of a complex of HDAC3 and PPAR?2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPAR?2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.

A cell culture system including a silk fibroid scaffold, culture media, and pancreatic cells. The pancreatic cells grown in the tissue culture system have physiological and morphological features like those of in vivo pancreatic cells. The cell culture system can be used to produce a pancreatic tissue-specific extracellular matrix capable of inducing differentiation of pancreatic cell precursors into pancreatic cells.

The present invention relates to the use of polysulfated polysaccharides in combination with progenitor cells to improve the viability of the progenitor cells including improving the cryopreservation of the progenitor cells and provides novel compositions, methods and uses. The present invention also relates to the use of polysulfated polysaccharides to regulate the proliferation and differentiation of progenitor cells.

The invention relates to implantable collagen devices made by seeding at least one elongate collagen construct, e.g., comprising at least one elongate synthetic collagen fiber with a plurality of cells and applying a strain and/or stress to the at least one elongate collagen fiber to induce the cells to differentiate into target phenotypes, e.g., tendon or ligament phenotype cells (and/or fibroblasts), typically with an extracellular matrix of collagen to organize into a tissue on the at least one collagen fiber.

Self-aligned fibrous scaffolds are disclosed. The scaffolds are capable of automechanoinduction of cell cultures and methods to induce authomechanoinduction in cancer cells and stem cells are disclosed as well.

The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.

The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitors, and methods and compositions for clinical applications in the field of regenerative medicine.

The application describes a contractile cellular biomaterial that is particularly well suited to regenerative therapy of tissue affected by myocardial infraction. The biomaterial comprises a contractile tissue which is contained in an optionally porous solid substrate. The contractile tissue is formed by differentiating stem cells, in particular mesenchymal stem cells. In addition to being contractile, the biomaterial can have inducible paracrine activity. The biomaterial has, in particular, the advantage of not needing to be frozen in order to be conserved.

The disclosure relates to methods, systems and compositions for use in promoting adipocytes differentiation for production of cultured fat ex-vivo. More precisely, the disclosure relates to methods, systems and compositions for use in selectively promoting adipocytes differentiation by exposing MSCs, to plant lecithins for production of cultured fat ex-vivo.

The present invention concerns a method of producing brown/beige adipocytes from white adipose tissue cells and/or mesenchymal stem cells, in particular from subcutaneous white adipose tissue cells, and the use of said brown/beige adipocytes in a cell based therapy of a subject or in screening platforms.